Form 4: Adaptive Biotechnologies Executive Exercises Stock Options
SEC Form 4 Filing
Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies, exercised stock options to acquire 5,000 shares of common stock at $1.98 per share.
Summary
- On October 8, 2024, Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies Corp, exercised stock options.
- This transaction involved the acquisition of 5,000 shares of common stock at a price of $1.98 per share.
- Following the transaction, Ms. Bobulsky directly owns 253,290 shares of Adaptive Biotechnologies Corp.
- The exercised stock options were fully exercisable as of October 13, 2024.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of an executive exercising stock options, which doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions. It provides transparency into the trading activities of company executives, which is a standard practice in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
- It provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 10/08/2024 | Date of stock option exercise and transaction. |
| 10/13/2024 | Date the options were fully exercisable. |
| 10/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.